Lung Cancer Management, 2016 In the era of high-throughput molecular screening and personalized medicine, difficulty in determining whether cancer mutations are truly 'actionable' remains a gray zone in NSCLC. The most important prerequisite to perform such investigations is the tumor tissue retrieval via biopsy at diagnosis and after occurrence of resistance.
Trombetta, D. +3 more
openaire +2 more sources
Frontiers in Oncology, 2012 The phosphatidylinositol 3-kinases (PI3Ks) are members of a family of intracellular lipid kinases that phosphorylate the 3'-hydroxyl group of phosphatidylinositol and phosphoinositides. PI3K regulate signaling pathways for neoplasia, including cell proliferation, adhesion, survival, and motility.
Martinez-Martí, Alex, Felip, Enriqueta
openaire +3 more sources
Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. [PDF]
, 2015 BackgroundKey effector(s) of mutated KRAS in lung cancer progression and metastasis are unknown. Here we investigated the role of PAK1/Crk axis in transduction of the oncogenic KRAS signal in non-small cell lung cancer (NSCLC).MethodsWe used NSCLC ...
Aljilani, Amir +7 more
core +2 more sources
Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer. [PDF]
, 2014 Somatic mutations of the epidermal growth factor receptor often cause resistance to therapy with tyrosine kinase inhibitor in non-small cell lung cancer (NSCLC). In this study, we aimed to identify partner drugs and pathways that can induce cell death in
Koeffler, H Phillip +5 more
core +7 more sources
Preoperative CYFRA 21-1 and CEA as Prognostic Factors in Patients with Stage I Non-Small Cell Lung Cancer [PDF]
, 2008 Objective: To validate the prognostic value of preoperative levels of CYFRA 21-1, CEA and the corresponding tumor marker index (TMI) in patients with stage I non-small cell lung cancer (NSCLC). Methods: Two hundred forty stage I NSCLC patients (80 in pT1
Ankerst, Donna Pauler +7 more
core +1 more source
Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping
Медицинский совет, 2021 Personalized therapy is starting to play an increasing role in modern approaches to the treatment of oncological diseases. The previously existing uniform standard for each malignant disease is expanded with new options and treatment possibilities ...
M. O. Mandrina +6 more
doaj +1 more source
miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. [PDF]
, 2015 MicroRNAs (miRNAs), a class of small non-coding RNAs, mediate gene expression by either cleaving target mRNAs or inhibiting their translation. They have key roles in the tumorigenesis of several cancers, including non-small cell lung cancer (NSCLC).
Cao, Yan +12 more
core +1 more source
A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer. [PDF]
, 2012 Metastatic non-small cell lung cancer (NSCLC) carries a dismal prognosis. Clinical evidence suggests the existence of an intermediate, or oligometastatic, state when metastases are limited in number and/or location.
Niibe, Yuzuru +4 more
core +3 more sources
The efficacy of durvalumab in locally advanced lung carcinoma [PDF]
Archive of OncologyBackground: The integration of durvalumab, an immune checkpoint inhibitor, as consolidation therapy following platinum-based chemoradiotherapy has redefined the standard of care for patients with stage III, unresectable non-small cell lung cancer (NSCLC)
Knežević Isidora +3 more
doaj +1 more source
Simple and objective prediction of survival in patients with lung cancer: staging the host systemic inflammatory response [PDF]
, 2014 Background. Prediction of survival in patients diagnosed with lung cancer remains problematical. The aim of the present study was to examine the clinical utility of an established objective marker of the systemic inflammatory response, the Glasgow ...
Brown, Louise +12 more
core +4 more sources